title: The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.
abstract: The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA; Section of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: katerina.politi@yale.edu.
authors.forename: Katerina
authors.initials: K
authors.lastname: Politi
authors.affiliation: Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
authors.forename: Deborah
authors.initials: D
authors.lastname: Ayeni
authors.affiliation: Section of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: thomas.lynch@yale.edu.
authors.forename: Thomas
authors.initials: T
authors.lastname: Lynch
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors